Symbiosis Pharmaceutical Services Completes Successful Sterile Inspection

The company’s Scotland-based facility has successfully completed a scheduled inspection by the UK’s MHRA; there were no critical or major observations noted.

Symbiosis Pharmaceutical Services, a CMO in parenteral manufacturing, announced that its Scotland-based facility has successfully completed a scheduled inspection by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). There were no critical or major observations noted.

Symbiosis has been re-inspected and approved for the ongoing production of investigational medicinal products for clinical trials. The company has received confirmation of continued authorization for the GMP manufacture of aseptically-filled licensed commercial products following initial approval of the commercial manufacturer’s/importers license in 2014.

Source: Symbiosis Pharmaceutical Services